Literature DB >> 26434595

TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition.

D J Pinato1, S Chowdhury2, J Stebbing1.   

Abstract

TAM (Tyro3-Axl-Mer) receptor tyrosine kinases and Met are implicated in several hallmarks of cancer progression including sustained angiogenesis, enhanced motility, tissue invasion and acquisition of metastatic potential through the upregulation of epithelial-to-mesenchymal transition. Increasing evidence has confirmed Axl and Met as emerging central drivers of adaptive resistance to targeted therapies across a wide variety of cancers. In this issue of Oncogene, Zhou et al. describe the mechanisms linking Axl and Met activation to acquired resistance to sunitinib in renal cell carcinoma (RCC), providing a pre-clinical rationale for the development of Axl and Met inhibitors including cabozantinib in anti-angiogenic resistant RCC.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26434595     DOI： 10.1038/onc.2015.374

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.

Authors:  I-K Park; B Mundy-Bosse; S P Whitman; X Zhang; S L Warner; D J Bearss; W Blum; G Marcucci; M A Caligiuri
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 3.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

4.  Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.

Authors:  K Vuoriluoto; H Haugen; S Kiviluoto; J-P Mpindi; J Nevo; C Gjerdrum; C Tiron; J B Lorens; J Ivaska
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 5.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

6.  Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Authors:  Amanda Kirane; Kathleen F Ludwig; Noah Sorrelle; Gry Haaland; Tone Sandal; Renate Ranaweera; Jason E Toombs; Miao Wang; Sean P Dineen; David Micklem; Michael T Dellinger; James B Lorens; Rolf A Brekken
Journal:  Cancer Res       Date:  2015-07-23       Impact factor: 12.701

Review 7.  The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?

Authors:  Viktor Grünwald; Axel Stuart Merseburger
Journal:  Eur J Cancer       Date:  2013-04-16       Impact factor: 9.162

8.  Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.

Authors:  Takeshi Yoshida; Guolin Zhang; Matthew A Smith; Alex S Lopez; Yun Bai; Jiannong Li; Bin Fang; John Koomen; Bhupendra Rawal; Kate J Fisher; Y Ann Chen; Michiko Kitano; Yume Morita; Haruka Yamaguchi; Kiyoko Shibata; Takafumi Okabe; Isamu Okamoto; Kazuhiko Nakagawa; Eric B Haura
Journal:  Clin Cancer Res       Date:  2014-06-11       Impact factor: 12.531

Review 9.  Molecular basis for sunitinib efficacy and future clinical development.

Authors:  Sandrine Faivre; George Demetri; William Sargent; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

10.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
View more
  9 in total

1.  Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Authors:  Marguerite L Palisoul; Jeanne M Quinn; Emily Schepers; Ian S Hagemann; Lei Guo; Kelsey Reger; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2017-09-13       Impact factor: 6.261

2.  Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Authors:  David Cella; Bernard Escudier; Nizar M Tannir; Thomas Powles; Frede Donskov; Katriina Peltola; Manuela Schmidinger; Daniel Y C Heng; Paul N Mainwaring; Hans J Hammers; Jae Lyun Lee; Bruce J Roth; Florence Marteau; Paul Williams; John Baer; Milan Mangeshkar; Christian Scheffold; Thomas E Hutson; Sumanta Pal; Robert J Motzer; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2018-01-29       Impact factor: 44.544

Review 3.  The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy.

Authors:  Magdalena Paolino; Josef M Penninger
Journal:  Cancers (Basel)       Date:  2016-10-21       Impact factor: 6.639

4.  Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma.

Authors:  David J Pinato; Matthew W Brown; Sebastian Trousil; Eric O Aboagye; Jamie Beaumont; Hua Zhang; Helen M Coley; Francesco A Mauri; Rohini Sharma
Journal:  Br J Cancer       Date:  2019-02-15       Impact factor: 7.640

Review 5.  AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.

Authors:  Chenjing Zhu; Yuquan Wei; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-11-04       Impact factor: 27.401

6.  MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.

Authors:  Dansaem Lim; Jin Gu Cho; Eunsik Yun; Aram Lee; Hong-Yeoul Ryu; Young Joo Lee; Sukjoon Yoon; Woochul Chang; Myeong-Sok Lee; Byung Su Kwon; Jongmin Kim
Journal:  Genes (Basel)       Date:  2020-12-23       Impact factor: 4.096

7.  Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer.

Authors:  Danh D Truong; Salah-Eddine Lamhamedi-Cherradi; Joseph A Ludwig
Journal:  J Bone Oncol       Date:  2022-02-24       Impact factor: 4.072

8.  Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma.

Authors:  Dongshan Chen; Chen Zhang; Yuanwei Zang; Wei Wang; Jiandong Zhang
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

Review 9.  Therapeutic Sequencing in Metastatic Renal Cell Carcinoma.

Authors:  Manuel Caitano Maia; Nazli Dizman; Meghan Salgia; Sumanta Kumar Pal
Journal:  Kidney Cancer       Date:  2017-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.